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Abstract
There is no ideal treatment for benign multinodular goitre. Besides surgery, which is recommended
for large goitres or when malignancy cannot be excluded, the non-surgical treatment options are
levothyroxine therapy and radioiodine (
131I) therapy. Conventional
131I therapy [without
recombinant human thyroid-stimulating hormone (rhTSH)] has been used for more than a decade
in symptomatic non-toxic multinodular goitre, and although it does lead to significant thyroid volume
reduction, relatively high activities of radioiodine are needed because of a frequent finding of a low
thyroid radioiodine uptake. rhTSH, even when used in very small doses in combination with
131I therapy, enhances the thyroid volume reduction at lower
131I activities by doubling the thyroid
radioiodine uptake. However, before rhTSH stimulation can be routinely used by clinicians to
optimise the
131I therapy in multinodular goitre, aspects of this association, such as the cost-benefit
and optimum rhTSH dose and safety, will have to be sufficiently clarified.
Introduction and context
Radioactive iodine has been used extensively for treat-
ment of hyperthyroidism for more than 60 years. As it
was noticed that the treatment not only alleviated the
hyperthyroid state but also caused goitres to shrink, this
therapy was introduced more than 20 years ago as a
possible treatment modality in the management of non-
toxic goitre [1-6]. The first reports described patients with
large multinodular goitres who for other reasons were
not eligible for surgery (for example, patients with
cardiac or respiratory failure). In one study, it was stated
that the use of radioactive iodine therapy constitutes an
alternative to surgery in selected patients with large
compressive goitres in whom surgery was contraindi-
cated because of age or other medical conditions [7].
Later, treatment was given to patients with diffuse non-
toxic goitre, all of whom had serious symptoms but
refused surgery [8].
The general treatment modalities for non-toxic goitre are
medical treatment with levothyroxine, surgery, and
radioactive iodine. Thyroxine treatment for diffuse
non-toxic goitre is a well-established modality in some
countries, especially in iodine-deficient regions where
often the disease affects more than 10% of the
population. A reduction in thyroid volume of 20-30%
within 3 months can be achieved but requires a
thyroxine dose that can lead to suppression of serum
thyrotropin, tissue thyrotoxicosis, and risk of osteo-
porosis [9,10]. Life-long treatment is necessary, yet most
patients will develop nodular thyroid disease, for which
thyroxine is much less effective.
Non-toxic multinodular goitres are more prevalent in
populations with low or borderline iodine intake. The
disease most often starts at a young age with a diffuse
enlargement that gradually becomes more nodular with
time and with increasing numbers of autonomously
functioning nodules [11,12]. At the nodular stage,
thyroxine therapy is inefficient in reducing thyroid
volume since thyrotropin starts to be suppressed by the
autonomous nodules, and therefore in most countries
surgery has been the only option for therapy [12,13].
A fear of increasing the thyroid gland through radiation
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colleagues [14], which demonstrated that the inspiratory
flow curve was not negatively affected after treatment
and that, on the contrary, there was a beneficial effect.
Another aspect has been the occurrence of thyroid
autoimmunity with a Graves’ disease-like reaction after
radioiodine therapy [15], in some cases accompanied by
thyroid-associated ophthalmopathy [16]. It has not yet
been resolved as to whether this is a de novo auto-
immunity; instead, it might be existing asymptomatic
Graves’ disease within a nodular goitre with a transitory
deterioration of the autoimmune process due to antigen
release after the destructive radiation. Finally, the
possibility of a thyroid tumour harboured in a nodular
goitre, though rare, must be kept in mind.
The introduction of radioiodine as a treatment modality
has advanced the management of these patients on the
one hand but has posed some problems on the other
hand since many of the populations who were initially
low in iodine have now started iodine salt addition
programmes, which notoriously lower the uptake of
radioiodine. The treatment success therefore is limited
and requires much greater amounts of radioiodine to
overcome this problem, thus creating a potential
environmental problem due to surplus radioiodine
excreted in the urine [17].
Recent advances
The problem of low iodine uptake has recently been
overcome by introducing recombinant human thyroid-
stimulating hormone (rhTSH) as a stimulator before the
radioiodine therapy [18-20]. In one of the studies, it was
shown that, followed by 1.11 GBq, a very low dose of
0.005 mg rhTSH was as safe and effective as 0.1 mg of
rhTSH. Both doses increased the efficacy of radioiodine.
Adverse events were mild, transient, and readily treatable
[19]. Other studies have verified that the uptake was
dramatically increased, even by low doses of rhTSH
[21,22], and the regional distribution of the uptake can
change substantially, thus providing the possibility for
efficient shrinkage of previous large cold nodules by even
a single low dose of rhTSH [23]. Subsequent studies have
investigated issues such as the amount of rhTSH to be
used, the timing, and the effect, even in persons with
normal thyroid glands [24-26]. As in radioiodine
treatment without pre-stimulation, there have been
several reports of thyroid enlargements after rhTSH,
and some of these enlargements have been very serious
[27-29]. However, the general picture shows a safe
procedure with a tendency to relieve local tracheal
symptoms [30]. An alternative to this treatment has
been presented as repeated doses of radioiodine rather
than pre-stimulation [31]. When used together, these
two modalities may prove to be beneficial in some very
difficult cases.
Implications for clinical practice
Although surgeons still advocate surgery as the treatment
of choice in non-toxic goitres [12,13], it seems clear to
most clinicians that radioactive iodine therapy is an
attractive alternative with few side effects and is easy for
the patient as it does not require hospitalisation. The
limitation of the therapy of having to use either very high
or repeated doses of radioiodine due to many large
goitres with low iodine uptake has been overcome by
pre-treatment with rhTSH [18-26]. Although this treat-
ment at present is rather expensive, it appears that much
smaller doses of the drug have sufficient efficacy, and the
price therefore should be adjusted by the production of
appropriate ampoule sizes. To further document a more
widespread use of rhTSH as a pre-treatment, additional
randomised clinical trials comparing doses of rhTSH and
comparing radioiodine therapy with surgery in terms of
outcome measures such as efficacy of goitre control,
thyroid function, health care costs, and health-related
quality of life are needed [32,33]. Only then can the
treatment continue based on solid evidence, which is
very likely to change treatment algorithms for non-toxic
goitre in the future [34].
Abbreviation
rhTSH, recombinant human thyroid-stimulating
hormone.
Competing interests
The author has received unrestricted research grants from
Genzyme (Cambridge, MA, USA) and has served on one
of the advisory boards of the same company.
References
1. Bell PR, Hegedüs L, Hansen JM: Radioactive iodine for thyrotoxi-
cosis. Lancet 1986, 2:339-40.
2. Hegedüs L, Hansen BM, Knudsen N, Hansen JM: Reduction of size
of thyroid with radioactive iodine in multinodular non-toxic
goitre. BMJ 1988, 297:661-2.
3. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM:
Radioiodine treatment of multinodular non-toxic goitre. BMJ
1993, 307:828-32.
4. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO,
Kloppenborg PW: Large, compressive goiters treated with
radioiodine. Ann Intern Med 1994, 121:757-62.
5. Wesche MF, Tiel-Van Buul MM, Smits NJ, Wiersinga WM: Reduction
in goiter size by
131I therapy in patients with non-toxic
multinodular goiter. Eur J Endocrinol 1995, 132:86-7.
6. Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM:
Determinants of longterm outcome of radioiodine therapy
of sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999, 50:783-9.
7. Verelst J, Bonnyns M, Glinoer D: Radioiodine therapy in
voluminous multinodular non-toxic goitre. Acta Endocrinol
(Copenh) 1990, 122:417-21.
Page 2 of 3
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:70 http://F1000.com/Reports/Medicine/content/1/708. Hegedüs L, Bennedbæk FN: Radioiodine for non-toxic diffuse
goitre. Lancet 1997, 350:409-10.
9. Hansen JM, Kampmann J, Madsen SN, Skovsted L, Solgaard S,
Grytter C, Grøntvedt T, Rasmussen SN: l-Thyroxine treatment
of diffuse non-toxic goitre evaluated by ultrasonic determina-
tion of thyroid volume. Clin Endocrinol (Oxf) 1979, 10:1-6.
10. Wesche MF, Tiel-Van Buul MM, Lips P, Smits NJ, Wiersinga WM:
A randomized trial comparing levothyroxine with radio-
active iodine in the treatment of sporadic nontoxic goiter.
J Clin Endocrinol Metab 2001, 86:998-1005.
11. Berghout A, Wiersinga WM, Smits NJ, Touber JL: Interrelation-
ships between age, thyroid volume, thyroid nodularity, and
thyroid function in patients with sporadic nontoxic goiter. Am
J Med 1990, 89:602-8.
12. Hegedüs L, Bonnema SJ, Bennedbæk FN: Management of simple
nodular goiter. Endocr Rev 2003, 24:102-32.
13. Bhagat MC, Dhaliwal SS, Bonnema SJ, Hegedüs L, Walsh JP:
Differences between endocrine surgeons and endocrinolo-
gists in the management of non-toxic multinodular goitre. Br J
Surg 2003, 90:1103-12.
14. Nygaard B, Soes-Petersen U, Hoilund-Carlsen PF, Veje A, Holst PE,
Vestergaard A, Solling K: Improvement of upper airway
obstruction after
131I -treatment of multinodular nontoxic
goiter evaluated by flow volume loop curves. J Endocrinol Invest
1996, 19:71-5.
15. Nygaard B, Knudsen JH, Hegedüs L, Scient AV, Hansen JE:
Thyrotropin receptor antibodies and Graves’ disease, a
side-effect of
131I treatment in patients with nontoxic goiter.
J Clin Endocrinol Metab 1997, 82:2926-30.
16. Nygaard B, Metcalfe RA, Phipps J, Weetman AP, Hegedüs L: Graves’
disease and thyroid associated ophthalmopathy triggered by
131I treatment of non-toxic goiter. J Endocrinol Invest 1999,
22:481-5.
17. Huysmans DA, Buijs WC, van de Ven MT, van den Broek WJ,
Kloppenborg PW, Hermus AR, Corstens FH: Dosimetry and risk
estimates of radioiodine therapy for large, multinodular
goiters. J Nucl Med 1996, 37:2072-9.
18. Nielsen VE, Bonnema SJ, Hegedüs L: Effects of 0.9 mg recombi-
nant human thyrotropin on thyroid size and function in
normal subjects: a randomized, double-blind, cross-over
trial. J Clin Endocrinol Metab 2004, 89:2242-7.
19. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, Schellekens AP, Bus JW,
Bravenboer B, Hermus AR: Administration of a single low dose
of recombinant human thyrotropin significantly enhances
thyroid radioiodide uptake in nontoxic nodular goiter. J Clin
Endocrinol Metab 2000, 85:3592-6.
20. Silva MN, Rubió IG, Romão R, Gebrin EM, Buchpiguel C, Tomimori E,
Camargo R, Cardia MS, Medeiros-Neto G: Administration of a
single dose of recombinant human thyrotrophin enhances
the efficacy of radioiodine treatment of large compressive
multinodular goitres. Clin Endocrinol (Oxf) 2004, 60:300-8.
21. Cubas ER, Paz-Filho GJ, Olandoski M, Goedert CA, Woellner LC,
Carvalho GA, Graf H: Recombinant human TSH increases the
efficacy of a fixed activity of radioiodine for treatment of
multinodular goitre. Int J Clin Pract 2009, 63:583-90.
22. Bonnema SJ, Nielsen VE, Hegedüs L: Radioiodine therapy in non-
toxic multinodular goitre. The possibility of effect-amplifica-
tion with recombinant human TSH (rhTSH). Acta Oncol 2006,
45:1051-8.
23. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, Corstens FH,
Huysmans DA: Pretreatment with recombinant human TSH
changes the regional distribution of radioiodine on thyroid
scintigrams of nodular goiters. J Clin Endocrinol Metab 2001,
86:5330-6.
24. Nielsen VE, Bonnema SJ, Hegedüs L: The effects of recombinant
human thyrotropin, in normal subjects and patients with
goitre. Clin Endocrinol (Oxf) 2004, 61:655-63.
25. Nieuwlaat WA, Hermus AR, Ross HA, Buijs WC, Edelbroek MA,
Bus JW, Corstens FH, Huysmans DA: Dosimetry of radioiodine
therapy in patients with nodular goiter after pretreatment
with a single, low dose of recombinant human thyroid-
stimulating hormone. J Nucl Med 2004, 45:626-33.
26. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH:
Effect of various doses of recombinant human thyrotropin on
the thyroid radioactive iodine uptake and serum levels of
thyroid hormones and thyroglobulin in normal subjects. J Clin
Endocrinol Metab 2001, 86:1660-4.
27. Braga M, Ringel MD, Cooper DS: Sudden enlargement of local
recurrent thyroid tumor after recombinant human TSH
administration. J Clin Endocrinol Metab 2001, 86:5148-51.
28. Goffman T, Ioffe V, Tuttle M, Bowers JT, Mason ME: Near lethal
respiratory failure after recombinant human thyroid stimu-
lating hormone use in a patient with metastatic thyroid
carcinoma. Thyroid 2003, 13:827-30.
29. Nielsen VE, Bonnema SJ, Hegedüs L: Transient goiter enlarge-
ment after administration of 0.3 mg recombinant human
thyrotropin in patients with benign nontoxic nodular goiter:
a randomized, double-blind, cross-over trial. J Clin Endocrinol
Metab 2006, 91:1317-22.
30. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, Grupe P, Andersen PB,
Bastholt L, Hegedüs L: Recombinant human thyrotropin-
stimulated radioiodine therapy of large nodular goiters
facilitates tracheal decompression and improves inspiration.
J Clin Endocrinol Metab 2008, 93:3981-4.
31. Baczyk M, Pisarek M, Czepczynski R, Ziemnicka K, Gryczynska M,
Pietz L, Sowinski J: Therapy of large multinodular goitre using
repeated doses of radioiodine. Nucl Med Commun 2009, 30:
226-31.
32. Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L,
Bjorner JB, Feldt-Rasmussen U: Quality of life in patients with
benign thyroid disorders. A review. Eur J Endocrinol 2006,
154:501-10.
33. Watt T, Rasmussen AK, Groenvold M, Bjorner JB, Watt SH,
Bonnema SJ, Hegedüs L, Feldt-Rasmussen U: Improving a newly
developed patient-reported outcome for thyroid patients,
using cognitive interviewing. Qual Life Res 2008, 17:1009-17.
34. Fast S, Nielsen VE, Bonnema SJ, Hegedüs L: Time to reconsider
nonsurgical therapy of benign non-toxic multinodular goitre:
focus on recombinant human TSH augmented radioiodine
therapy. Eur J Endocrinol 2009, 160:517-28.
Page 3 of 3
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:70 http://F1000.com/Reports/Medicine/content/1/70